RUSNANO’s Subsidiary Sells Its Stake in American Company Tobira

21 September 2016

A subsidiary of RUSNANO, RusnanoMedInvest, withdraws from the capital of Tobira Therapeutics, a company developing drugs for the treatment of liver diseases, inflammatory diseases, fibrosis, and HIV infection. The buyer is Allergan, one of the world’s largest pharmaceutical companies.

“We are satisfied with the results of the largest transaction on the global pharmaceutical market. Its results confirm that we have correctly identified life science as a sphere for investment. We will use our proceeds from this transaction, inter alia, for creation of ‘Big Pharma’ in Russia,” said Chairman of the Board of MC RUSNANO Anatoly Chubais commenting on the transaction.

Additional information

Reference

RUSNANO Joint-Stock Company was founded in March 2011 through reorganization of state corporation Russian Corporation of Nanotechnologies. JSC RUSNANO contributes to implementation of the state policy on the development of the nanotechnology industry by investing directly and through investment funds of nanotechnology in financially effective high-technology projects providing the development of new production facilities in the Russian Federation. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. 100 percent of RUSNANO’s shares are state owned. Thanks to RUSNANO’s investments, there are currently 95 factories and R&D Centers opened in 37 regions in Russia.

Management of assets of RUSNANO JSC is carried out by Limited Liability Company established in December 2013, RUSNANO Management Company. Anatoly Chubais is the Chairman of its Executive Board.

Work to establish nanotechnology infrastructure and carry out educational programs is fulfilled by RUSNANO’s Fund for Infrastructure and Educational Programs, which was also established during the reorganization of the Russian Corporation of Nanotechnologies.